We provide innovative medical propellants to the world’s biggest pharmaceutical companies. All of our products are produced to the most demanding industry standards at our dedicated facilities. Find out more about our global community.
Zephex® 152a: reducing the carbon footprint of asthma inhalers
Zephex® 152a: reducing the carbon footprint of asthma inhalersFind out more
Zephex® 152a will reduce the carbon footprint by 90% compared to current metered dose inhalers. Our low GWP medical propellant is a commitment to both end users and our environment.
From the Newsroom
RDD 2022 Recap: 152a features across event agenda
2022 is a significant year for 152a (Zephex) with key commercialization milestones being met and this was seen at RDD 2022 held in Orlando FloridaRead more
HFA 152a: Roadmap to commercialization
Zephex® 152a – RDD 2022 Workshop presentation Click here: LINK Recorded for the RDD 2022 workshop May 1 With growing interest in the adoption ofRead more
Koura opens world’s first HFA 152a medical propellant production facility
• New HFA 152a production facility will produce low global warming potential (GWP) propellants for pressurised metered dose inhalers (pMDIs). • The new propellant willRead more
- RDD 2023 – Nice, France (2nd – 5th May)